Get the Stockscreener App
274.38
1.35%
-3.87
Alnylam Pharmaceuticals Inc stock is traded at $274.38, with a volume of 235.54K.
It is down -1.35% in the last 24 hours and up +16.34% over the past month.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.
See More
Previous Close:
$278.25
Open:
$276.91
24h Volume:
235.54K
Relative Volume:
0.34
Market Cap:
$35.89B
Revenue:
$2.09B
Net Income/Loss:
$-332.26M
P/E Ratio:
-104.73
EPS:
-2.62
Net Cash Flow:
$16.06M
1W Performance:
+1.18%
1M Performance:
+16.34%
6M Performance:
+5.51%
1Y Performance:
+62.81%
1-Day Range:
$272.35
$278.03
1-Week Range:
$266.21
$279.24
52-Week Range:
$141.97
$304.39
Alnylam Pharmaceuticals Inc Stock (ALNY) Company Profile
Name
Alnylam Pharmaceuticals Inc
Sector
Industry
Phone
(617) 551-8200
Address
675 WEST KENDALL STREET, CAMBRIDGE, MA
Compare ALNY with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALNY
Alnylam Pharmaceuticals Inc
|
274.51 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
VRTX
Vertex Pharmaceuticals Inc
|
473.20 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
715.22 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
653.00 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
BNTX
Biontech Se Adr
|
118.25 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Alnylam Pharmaceuticals Inc Stock (ALNY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-12-24 | Downgrade | Wolfe Research | Peer Perform → Underperform |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Aug-16-24 | Upgrade | Goldman | Neutral → Buy |
| Feb-16-24 | Downgrade | Goldman | Buy → Neutral |
| Feb-15-24 | Initiated | Wolfe Research | Peer Perform |
| Dec-08-23 | Initiated | Wells Fargo | Equal Weight |
| Oct-11-23 | Downgrade | Oppenheimer | Outperform → Perform |
| Sep-29-23 | Initiated | Raymond James | Outperform |
| May-05-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Apr-26-23 | Initiated | SMBC Nikko | Neutral |
| Mar-21-23 | Initiated | Bernstein | Outperform |
| Jan-18-23 | Initiated | Canaccord Genuity | Buy |
| Sep-09-22 | Resumed | Morgan Stanley | Equal-Weight |
| Jul-13-22 | Initiated | Cantor Fitzgerald | Neutral |
| Jun-27-22 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-07-22 | Initiated | William Blair | Outperform |
| Apr-25-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Mar-01-22 | Initiated | Citigroup | Buy |
| Feb-03-22 | Upgrade | Guggenheim | Neutral → Buy |
| Jan-03-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Nov-22-21 | Upgrade | Goldman | Neutral → Buy |
| Nov-22-21 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-01-21 | Upgrade | Oppenheimer | Perform → Outperform |
| Oct-04-21 | Upgrade | UBS | Neutral → Buy |
| Aug-04-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Feb-22-21 | Downgrade | Guggenheim | Buy → Neutral |
| Feb-12-21 | Downgrade | Citigroup | Buy → Neutral |
| Feb-12-21 | Reiterated | H.C. Wainwright | Buy |
| Jan-25-21 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Sep-30-20 | Resumed | Berenberg | Hold |
| Sep-08-20 | Initiated | Citigroup | Buy |
| Aug-11-20 | Downgrade | Oppenheimer | Outperform → Perform |
| May-13-20 | Initiated | RBC Capital Mkts | Sector Perform |
| May-07-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Apr-24-20 | Resumed | Evercore ISI | Outperform |
| Mar-19-20 | Initiated | Berenberg | Buy |
| Dec-19-19 | Reiterated | Chardan Capital Markets | Buy |
| Nov-20-19 | Initiated | Oppenheimer | Outperform |
| Nov-13-19 | Initiated | BofA/Merrill | Buy |
| May-23-19 | Resumed | Goldman | Neutral |
| Apr-12-19 | Initiated | Evercore ISI | Outperform |
| Mar-06-19 | Upgrade | Evercore ISI | In-line → Outperform |
| Mar-05-19 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jan-23-19 | Initiated | UBS | Neutral |
| Oct-01-18 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-13-18 | Reiterated | Stifel | Buy |
| Aug-07-18 | Upgrade | Stifel | Hold → Buy |
| May-04-18 | Reiterated | Stifel | Hold |
| Mar-28-18 | Initiated | Evercore ISI | In-line |
View All
Alnylam Pharmaceuticals Inc Stock (ALNY) Latest News
Strategic Financial Concepts LLC Invests $41.53 Million in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - MarketBeat
1,022 Shares in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Acquired by Chicago Partners Investment Group LLC - MarketBeat
SG Americas Securities LLC Lowers Stock Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - MarketBeat
PCSK9 Inhibitor Market Dynamics and Strategies for Success - openPR
RARE Reports New Upbeat Data From Sanfilippo Syndrome Drug Study - Yahoo Finance
Alnylam Pharmaceuticals (ALNY) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release - Yahoo Finance
U.S. Capital Wealth Advisors LLC Lowers Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - MarketBeat
abrdn plc Lowers Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - MarketBeat
Alnylam Pharmaceuticals (ALNY) Projected to Post Quarterly Earnings on Thursday - MarketBeat
China Universal Asset Management Co. Ltd. Buys 2,657 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - MarketBeat
Alnylam Pharmaceuticals' SWOT analysis: promising outlook for ATTR-CM stock - MSN
Mediolanum International Funds Ltd Sells 1,135 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - MarketBeat
(ALNY) Trading Report - Stock Traders Daily
259,913 Shares in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Acquired by Jennison Associates LLC - MarketBeat
Swedbank AB Grows Stock Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - MarketBeat
Robeco Institutional Asset Management B.V. Boosts Stock Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - MarketBeat
Goldman adds Alnylam, BofA, Raymond James to conviction list By Investing.com - Investing.com South Africa
Goldman adds Alnylam, BofA, Raymond James to conviction list - MSN
Bet on These 4 Top-Performing Liquid Stocks for Solid Gains - Yahoo Finance
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Holdings Lifted by SteelPeak Wealth LLC - MarketBeat
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Receives $298.61 Consensus Target Price from Analysts - MarketBeat
Baader Bank Aktiengesellschaft Lowers Holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - MarketBeat
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) CMO Pushkal Garg Sells 52,592 Shares - MarketBeat
Sivik Global Healthcare LLC Purchases Shares of 7,000 Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - MarketBeat
Forsta AP Fonden Boosts Stock Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - MarketBeat
What is Zacks Research's Forecast for ALNY Q2 Earnings? - MarketBeat
What is Zacks Research's Estimate for ALNY Q1 Earnings? - MarketBeat
Alnylam Pharmaceuticals CMO sells shares worth $14.99 million - MSN
Brighton Jones LLC Makes New Investment in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - MarketBeat
$1000 Invested In This Stock 15 Years Ago Would Be Worth This Much Today - Benzinga
Alnylam's Crucial 2024 Financial Results Coming: Key Date for Biotech Investors - StockTitan
Alnylam Pharmaceuticals CMO sells shares worth $14.99 million By Investing.com - Investing.com Nigeria
Alnylam Pharmaceuticals' SWOT analysis: stock poised for growth amid ATTR-CM opportunity - MSN
Alnylam Pharmaceuticals' SWOT analysis: stock poised for growth amid ATTR-CM opportunity By Investing.com - Investing.com South Africa
New Strong Buy Stocks for January 27th - MSN
Hypertension Clinical and Non-Clinical Studies, Key - openPR
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Stock Position Boosted by Nisa Investment Advisors LLC - MarketBeat
Park Avenue Securities LLC Boosts Stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - Defense World
Alnylam Pharmaceuticals Inc Stock (ALNY) Financials Data
Revenue
Net Income
Cash Flow
EPS
Alnylam Pharmaceuticals Inc Stock (ALNY) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Garg Pushkal | CMO & EVP Dev & Med Affairs |
Jan 27 '25 |
Sale |
285.00 |
52,592 |
14,988,720 |
11,989 |
0.83%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):